Aside from the possibility of Ovarian Hyperstimulation Syndrome (see WARNINGS - Overstimulation of the Ovary During Follistim® AQ (follitropin beta) Therapy) and multiple gestations (see WARNINGS - Multiple Births), there is no additional information concerning the consequences of acute overdosage with Follistim® AQ (follitropin beta injection).

Follistim® AQ (follitropin beta injection) is contraindicated in women who exhibit:

1. Prior hypersensitivity to recombinant hFSH products.
2. High levels of FSH indicating primary ovarian failure.
3. Uncontrolled thyroid or adrenal dysfunction.
4. Tumor of the ovary, breast, uterus, hypothalamus or pituitary gland.
5. Pregnancy.
6. Heavy or irregular vaginal bleeding of undetermined origin.
7. Ovarian cysts or enlargement not due to polycystic ovary syndrome (PCOS).
8. Hypersensitivity reactions to streptomycin or neomycin. Follistim® AQ (follitropin beta) may contain traces of these antibiotics and may cause hypersensitivity reactions in susceptible persons.

Last reviewed on RxList: 11/17/2008
This monograph has been modified to include the generic and brand name in many instances.